DK2332976T3 - Nye polypeptider, der er involveret ved et immunrespons - Google Patents

Nye polypeptider, der er involveret ved et immunrespons

Info

Publication number
DK2332976T3
DK2332976T3 DK10010891.9T DK10010891T DK2332976T3 DK 2332976 T3 DK2332976 T3 DK 2332976T3 DK 10010891 T DK10010891 T DK 10010891T DK 2332976 T3 DK2332976 T3 DK 2332976T3
Authority
DK
Denmark
Prior art keywords
immune response
novel polypeptides
polypeptides involved
involved
novel
Prior art date
Application number
DK10010891.9T
Other languages
English (en)
Inventor
Steven Kiyoshi Yoshinaga
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of DK2332976T3 publication Critical patent/DK2332976T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
DK10010891.9T 1999-02-03 2000-01-27 Nye polypeptider, der er involveret ved et immunrespons DK2332976T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24444899A 1999-02-03 1999-02-03
US26452799A 1999-03-08 1999-03-08
EP00907027.7A EP1149114B1 (en) 1999-02-03 2000-01-27 Polypeptides involved in immune response

Publications (1)

Publication Number Publication Date
DK2332976T3 true DK2332976T3 (da) 2014-06-23

Family

ID=26936541

Family Applications (3)

Application Number Title Priority Date Filing Date
DK10010891.9T DK2332976T3 (da) 1999-02-03 2000-01-27 Nye polypeptider, der er involveret ved et immunrespons
DK10010892.7T DK2332978T3 (da) 1999-02-03 2000-01-27 Nye polypeptider, der er involveret ved et immunrespons
DK00907027.7T DK1149114T3 (da) 1999-02-03 2000-01-27 Polypeptider, der er involveret ved et immunrespons

Family Applications After (2)

Application Number Title Priority Date Filing Date
DK10010892.7T DK2332978T3 (da) 1999-02-03 2000-01-27 Nye polypeptider, der er involveret ved et immunrespons
DK00907027.7T DK1149114T3 (da) 1999-02-03 2000-01-27 Polypeptider, der er involveret ved et immunrespons

Country Status (18)

Country Link
US (3) US20080152651A1 (da)
EP (4) EP1149114B1 (da)
JP (2) JP5000804B2 (da)
KR (1) KR20010101987A (da)
CN (1) CN1309734C (da)
AU (1) AU773954B2 (da)
CA (2) CA2640956C (da)
CY (3) CY1115099T1 (da)
DK (3) DK2332976T3 (da)
ES (3) ES2464156T3 (da)
HK (2) HK1159128A1 (da)
HU (1) HUP0105337A3 (da)
IL (3) IL144635A0 (da)
NZ (3) NZ551331A (da)
PT (3) PT1149114E (da)
SI (3) SI1149114T1 (da)
TW (1) TWI274058B (da)
WO (1) WO2000046240A2 (da)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7112655B1 (en) 1997-02-27 2006-09-26 Japan Tobacco, Inc. JTT-1 protein and methods of inhibiting lymphocyte activation
JP3521382B2 (ja) 1997-02-27 2004-04-19 日本たばこ産業株式会社 細胞間接着及びシグナル伝達を媒介する細胞表面分子
DE19821060A1 (de) * 1997-09-23 1999-04-15 Bundesrepublik Deutschland Let Ko-stimulierendes Polypeptid von T-Zellen, monoklonale Antikörper sowie die Herstellung und deren Verwendung
US7435796B1 (en) 1999-02-03 2008-10-14 Amgen Inc. Antibodies which bind B7RP1
US8624010B1 (en) 1999-02-03 2014-01-07 Steven K. Yoshinaga Nucleic acids encoding B7RP1
US7708993B2 (en) * 1999-02-03 2010-05-04 Amgen Inc. Polypeptides involved in immune response
DK2332976T3 (da) * 1999-02-03 2014-06-23 Amgen Inc Nye polypeptider, der er involveret ved et immunrespons
WO2001012658A2 (en) * 1999-08-11 2001-02-22 Isis Innovations Limited Human icos ligand and application thereof
JP4210454B2 (ja) * 2001-03-27 2009-01-21 日本たばこ産業株式会社 炎症性腸疾患治療剤
JP3871503B2 (ja) 1999-08-30 2007-01-24 日本たばこ産業株式会社 免疫性疾患治療剤
WO2001021796A2 (en) 1999-09-21 2001-03-29 Genetics Institute, Inc. Gl50 molecules and uses therefor
EP1900816A3 (en) * 1999-09-21 2008-03-26 Genetics Institute, LLC GL50 molecules and uses therefor
JP3597140B2 (ja) * 2000-05-18 2004-12-02 日本たばこ産業株式会社 副刺激伝達分子ａｉｌｉｍに対するヒトモノクローナル抗体及びその医薬用途
ES2536653T3 (es) * 2000-11-28 2015-05-27 Amgen Inc. Polipéptidos implicados en la respuesta inmunitaria
EP1349936A2 (en) * 2001-01-04 2003-10-08 Bayer Aktiengesellschaft Regulation of human b7-h2 protein
JP2005501516A (ja) * 2001-01-16 2005-01-20 キュラジェン コーポレイション タンパク質、そのタンパク質をコードするポリヌクレオチドおよびこれらの使用方法
WO2002074803A2 (en) * 2001-01-16 2002-09-26 Bayer Aktiengesellschaft Regulation of human icos v protein
JP4212278B2 (ja) * 2001-03-01 2009-01-21 日本たばこ産業株式会社 移植片拒絶反応抑制剤
YU103003A (sh) 2001-06-26 2006-05-25 Abgenix Inc. Antitela za opgl
EP1740617B1 (en) 2004-04-23 2013-10-16 BUNDESREPUBLIK DEUTSCHLAND letztvertreten durch das Robert Koch-Institut vertreten durch seinen Präsidenten Method for the treatment of t cell mediated conditions by depletion of icos-positive cells in vivo
EP1909831A4 (en) * 2005-06-14 2013-02-20 Amgen Inc PREPARATIONS OF SPONTANEOUS TAMPING PROTEINS
AU2013203437A1 (en) * 2005-07-18 2013-05-02 Amgen Inc. Human anti-B7RP1 neutralizing antibodies
EP2388276A3 (en) * 2005-07-18 2013-11-27 Amgen, Inc Human anti-B7RP1 neutralizing antibodies
AU2011265342B2 (en) * 2005-07-18 2014-12-04 Amgen Inc. Human anti-B7RP1 neutralizing antibodies
NZ568015A (en) 2005-12-08 2012-03-30 Medarex Inc Human monoclonal antibodies to O8E
JOP20140087B1 (ar) 2013-03-13 2021-08-17 Amgen Inc بروتينات مخصصة ل baff و b7rp1 وإستخداماتها
US9458246B2 (en) 2013-03-13 2016-10-04 Amgen Inc. Proteins specific for BAFF and B7RP1
EP3988920A1 (en) * 2014-04-16 2022-04-27 Juno Therapeutics GmbH Methods, kits and apparatus for expanding a population of cells
EP3253876B1 (en) * 2015-02-06 2020-11-04 Heat Biologics, Inc. Vector co-expressing vaccine and costimulatory molecules
CN107530428B (zh) 2015-03-23 2022-05-13 震动疗法股份有限公司 Icos的抗体
ITUB20151014A1 (it) 2015-05-27 2016-11-27 Univ Degli Studi Del Piemonte Orientale Amedeo Avogadro Ligandi del recettore b7h nel trattamento di osteopenia e osteoporosi
AU2016342269A1 (en) 2015-10-22 2018-03-29 Jounce Therapeutics, Inc. Gene signatures for determining icos expression
JP6884858B2 (ja) 2016-10-21 2021-06-09 アムジエン・インコーポレーテツド 医薬製剤及びその製造方法
EP3502140A1 (en) * 2017-12-21 2019-06-26 F. Hoffmann-La Roche AG Combination therapy of tumor targeted icos agonists with t-cell bispecific molecules

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US4615885A (en) 1983-11-01 1986-10-07 Terumo Kabushiki Kaisha Pharmaceutical composition containing urokinase
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
US4970154A (en) 1987-10-09 1990-11-13 Baylor College Of Medicine Method for inserting foreign genes into cells using pulsed radiofrequency
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5158881A (en) 1987-11-17 1992-10-27 Brown University Research Foundation Method and system for encapsulating cells in a tubular extrudate in separate cell compartments
US5106627A (en) 1987-11-17 1992-04-21 Brown University Research Foundation Neurological therapy devices
US5672344A (en) 1987-12-30 1997-09-30 The Regents Of The University Of Michigan Viral-mediated gene transfer system
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
ATE135370T1 (de) 1988-12-22 1996-03-15 Kirin Amgen Inc Chemisch modifizierte granulocytenkolonie erregender faktor
US5776963A (en) * 1989-05-19 1998-07-07 Hoechst Marion Roussel, Inc. 3-(heteroaryl)-1- (2,3-dihydro-1h-isoindol-2-yl)alkyl!pyrrolidines and 3-(heteroaryl)-1- (2,3-dihydro-1h-indol-1-yl)alkyl!pyrrolidines and related compounds and their therapeutic untility
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5676954A (en) 1989-11-03 1997-10-14 Vanderbilt University Method of in vivo delivery of functioning foreign genes
US5580756A (en) * 1990-03-26 1996-12-03 Bristol-Myers Squibb Co. B7Ig fusion protein
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
WO1995005452A2 (en) 1993-08-12 1995-02-23 Cytotherapeutics, Inc. Improved compositions and methods for the delivery of biologically active molecules using genetically altered cells contained in biocompatible immunoisolatory capsules
US6268212B1 (en) 1993-10-18 2001-07-31 Amgen Inc. Tissue specific transgene expression
US5484720A (en) 1994-09-08 1996-01-16 Genentech, Inc. Methods for calcium phosphate transfection
JPH11506722A (ja) 1995-06-07 1999-06-15 ベイラー・カレッジ・オブ・メディスン 細胞に核酸を送達するための核酸運搬体
US5679559A (en) 1996-07-03 1997-10-21 University Of Utah Research Foundation Cationic polymer and lipoprotein-containing system for gene delivery
JP3521382B2 (ja) 1997-02-27 2004-04-19 日本たばこ産業株式会社 細胞間接着及びシグナル伝達を媒介する細胞表面分子
US7112655B1 (en) * 1997-02-27 2006-09-26 Japan Tobacco, Inc. JTT-1 protein and methods of inhibiting lymphocyte activation
DE19821060A1 (de) * 1997-09-23 1999-04-15 Bundesrepublik Deutschland Let Ko-stimulierendes Polypeptid von T-Zellen, monoklonale Antikörper sowie die Herstellung und deren Verwendung
US7259247B1 (en) * 1997-09-23 2007-08-21 Bundersrespublik Deutschaland Letztvertreten Durch Den Direktor Des Robert-Koch-Institutes Anti-human T-cell costimulating polypeptide monoclonal antibodies
US7435796B1 (en) * 1999-02-03 2008-10-14 Amgen Inc. Antibodies which bind B7RP1
US7708993B2 (en) * 1999-02-03 2010-05-04 Amgen Inc. Polypeptides involved in immune response
DK2332976T3 (da) 1999-02-03 2014-06-23 Amgen Inc Nye polypeptider, der er involveret ved et immunrespons
WO2001012658A2 (en) 1999-08-11 2001-02-22 Isis Innovations Limited Human icos ligand and application thereof
JP3871503B2 (ja) 1999-08-30 2007-01-24 日本たばこ産業株式会社 免疫性疾患治療剤
EP1900816A3 (en) 1999-09-21 2008-03-26 Genetics Institute, LLC GL50 molecules and uses therefor
WO2001021796A2 (en) * 1999-09-21 2001-03-29 Genetics Institute, Inc. Gl50 molecules and uses therefor
WO2001064704A1 (en) 2000-03-02 2001-09-07 Mayo Foundation For Medical Education And Research hB7-H2, A NOVEL CO-STIMULATORY MOLECULE
US6635750B1 (en) 2000-07-20 2003-10-21 Millennium Pharmaceuticals, Inc. B7-H2 nucleic acids, members of the B7 family
US7030255B2 (en) * 2004-03-09 2006-04-18 Lyondell Chemical Technology, L.P. Oxidation process with in-situ H202 generation and polymer-encapsulated catalysts therefor
EP2388276A3 (en) * 2005-07-18 2013-11-27 Amgen, Inc Human anti-B7RP1 neutralizing antibodies
US8615703B2 (en) 2010-06-04 2013-12-24 Micron Technology, Inc. Advanced bitwise operations and apparatus in a multi-level system with nonvolatile memory

Also Published As

Publication number Publication date
EP1149114A2 (en) 2001-10-31
CA2362126A1 (en) 2000-08-10
EP1149114B1 (en) 2014-04-02
JP5658695B2 (ja) 2015-01-28
WO2000046240A3 (en) 2000-12-21
EP2332978B1 (en) 2014-04-02
EP2332976B1 (en) 2014-04-02
EP2332978A1 (en) 2011-06-15
PT2332978E (pt) 2014-05-23
AU2859200A (en) 2000-08-25
AU773954B2 (en) 2004-06-10
US8470317B2 (en) 2013-06-25
CA2640956A1 (en) 2000-08-10
JP2012110333A (ja) 2012-06-14
DK2332978T3 (da) 2014-06-23
CN1346370A (zh) 2002-04-24
NZ583002A (en) 2011-12-22
US20090208504A1 (en) 2009-08-20
CN1309734C (zh) 2007-04-11
HUP0105337A2 (hu) 2002-04-29
NZ513349A (en) 2004-03-26
IL229857A0 (en) 2014-01-30
CY1115099T1 (el) 2016-12-14
EP2796465A1 (en) 2014-10-29
US20140256652A1 (en) 2014-09-11
IL144635A0 (en) 2002-05-23
WO2000046240A2 (en) 2000-08-10
EP2332976A1 (en) 2011-06-15
TWI274058B (en) 2007-02-21
IL144635A (en) 2014-05-28
KR20010101987A (ko) 2001-11-15
CY1115102T1 (el) 2016-12-14
DK1149114T3 (da) 2014-06-23
ES2464161T3 (es) 2014-05-30
PT2332976E (pt) 2014-05-23
JP5000804B2 (ja) 2012-08-15
PT1149114E (pt) 2014-05-22
SI2332978T1 (sl) 2014-08-29
JP2002539770A (ja) 2002-11-26
SI1149114T1 (sl) 2014-08-29
CA2362126C (en) 2017-01-17
HK1159128A1 (en) 2012-07-27
ES2464156T3 (es) 2014-05-30
HK1159127A1 (en) 2012-07-27
HUP0105337A3 (en) 2011-01-28
SI2332976T1 (sl) 2014-08-29
NZ551331A (en) 2008-08-29
CY1115101T1 (el) 2016-12-14
ES2464165T3 (es) 2014-05-30
US20080152651A1 (en) 2008-06-26
CA2640956C (en) 2012-07-03

Similar Documents

Publication Publication Date Title
DK2332976T3 (da) Nye polypeptider, der er involveret ved et immunrespons
NO20040747L (no) Apparat med en aktuator omfattende et ringformet stempel.
NO20014518D0 (no) Nye forbindelser
DK1202994T3 (da) Nye forbindelser
NO20001483D0 (no) Nye NPY-agonister
NO20021436L (no) Nye forbindelser
DE60025241D1 (de) HäMOPOIETINREZEPTOR-PROTEIN, NR12
DK1235558T3 (da) Sammenpresset tabletsammensætning, der omfatter et NSAID
IT1316230B1 (it) Complesso di essiccazione.
NO20020810L (no) Nye fenylpiperaziner
DE60014662D1 (de) Verbesserungen in der schadstoffausstossregelung
NO20015383L (no) Nye forbindelser
BR0008833B1 (pt) Êmbolo construÍdo.
AU1796902A (en) Novel polypeptides involved in immune response
NO995945D0 (no) Nye forbindelser
NO20015374D0 (no) Nye forbindelser
NO20014629L (no) Nye forbindelser
ATE297923T1 (de) In 5-stellung substituierte 3-oxadiazolyl-1,6- naphthyridin-2(1h)-on-derivate
NO20016273D0 (no) Nye forbindelser
ES1041748Y (es) Pantalon perfeccionado.
DE60007034D1 (de) Verbesserte Sortiervorrichtung
DE60015819D1 (de) Pyrazolopyridinon als Zwischenprodukt
ES1044794Y (es) Lapida perfeccionada.
TR199902067A3 (tr) On bitki özlü sampuan.
IT249377Y1 (it) Gruppo vericello portatile.